InnovHeart is a medical technology startup that operates in the burgeoning field of mitral valve replacement. The company's primary product is the Saturn Transcatheter Mitral Valve Replacement (TMVR) system, a novel technology that aims to improve the quality of life for millions of people suffering from heart valve diseases. The technology was developed by a team of renowned doctors and researchers, including Dr. Lauren S. Ranard and Dr. Torsten Vahl, in collaboration with the Skirball Center for Innovation and InnovHeart's own R&D team.

The company's business model revolves around the development, licensing, and commercialization of its Saturn TMVR device. InnovHeart recently secured $55 million in Series C financing to further develop this technology. Additionally, the company has entered into an exclusive license agreement with the Grand Pharmaceutical Group to develop and commercialize the Saturn TMVR device in Greater China, indicating a strategic expansion into the Asian market.

InnovHeart is led by David James Wilson, an experienced healthcare and medical device executive, who was recently appointed as the company's CEO. Under his leadership, the company is expected to guide the Saturn TMVR program into its next phase of growth.

InnovHeart's commitment to innovation and learning is evident in its approach to business. The company believes that success lies in continuous innovation and that what worked yesterday may not be sufficient for tomorrow. This philosophy is likely to drive the company's future growth and success in the rapidly evolving MedTech industry.

Keywords: InnovHeart, MedTech, Saturn TMVR, Transcatheter Mitral Valve Replacement, Heart Valve Diseases, Series C Financing, Grand Pharmaceutical Group, China Market, David James Wilson, Continuous Innovation.